The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
A risk prediction model based on high-resolution computed tomography (HRCT) variables appear useful for patients with rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), suggests a study.
Despite the lack of significant contrast use, nearly one in six patients undergoing transcatheter mitral valve repair (MitraClip) develop acute kidney injury (AKI), which is associated with device failure or other severe conditions, according to a study.
A pulmonary rehabilitation programme for chronic obstructive pulmonary disease (COPD) yields sustained improvements in anxiety and quality of life of patients over 2 years, a study has shown. However, the positive changes in dyspnoea, depression, and stress symptoms may only last short term.
At the recent Pfizer webinar “Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?”, Dr Petrick Periyasamy, head of the Hospital Canselor Tuanku Muhriz UKM Infectious Diseases Unit, discussed the currently known epidemiology of adult pneumococcal disease (PD),as well as the impact of vaccines on PD prevention in at-risk populations.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.